Government-Owned Inventions; Availability for Licensing, 17846-17847 [2021-06997]

Download as PDF 17846 Federal Register / Vol. 86, No. 64 / Tuesday, April 6, 2021 / Notices Title of the Collection: SF–428 Tangible Personal Property Report. Type of Collection: Reinstatement of an expired information collection. OMB No.: 4040–0018. Abstract: Reporting on the status of Federally-owned property, including disposition, is necessitated in 2 CFR part 215, the ‘‘Uniform Administrative Requirements for Grants and Agreements with Institutions of Higher Education, Hospitals, and Other NonProfit Organizations’’, and the ‘‘Uniform Administrative Requirements for Grants and Agreements with State and Local Governments’’, Additionally, Public Law 106–107, the Federal Financial Assistance Management Improvement Act requires that agencies ’’simplify Federal financial assistance application and reporting requirements.’’ 31 U.S.C. 6101, Section 3. Agencies are currently using a variety of forms to account for both Federallyowned and grantee owned equipment and property. During the public consultation process mandated by Public Law 106–107, grant recipients requested a standard form to help them submit appropriate property information when required. The Public Law 106–107 Post Awards Subgroup developed a new standard form, the Tangible Personal Property Report, for submission of the required data. The form consists of the cover sheet (SF– 428), three attachments to be used as required: Annual Report, SF–428–A; Final Report, SF–428–B; Disposition Request/Report, SF–428–C and a Supplemental Sheet, SF–428S to provide detailed individual item information when required. Changes shall be made to the form and instructions of the SF–428–B and the SF–428–C. ANNUALIZED BURDEN HOUR TABLE Respondents (if necessary) SF–428 Tangible Personal Property Report. Grant applicants ............................. 2,000 1 1 2,000 Total ......................................... ......................................................... 2,000 1 1 2,000 Sherrette A. Funn, Paperwork Reduction Act Report Clearance Officer, Office of the Secretary. [FR Doc. 2021–07039 Filed 4–5–21; 8:45 am] BILLING CODE 4151–AE–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Amy F. Petrik, Ph.D., 240–627–3721; amy.petrik@nih.gov. Licensing information and copies of the U.S. patent application listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:34 Apr 05, 2021 Jkt 253001 Number of respondents Number of responses per respondents Forms 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows: Newcastle Disease Virus-Like Particle Displaying Prefusion Stabilized SARS– CoV–2 Spike and Its Use Description of Technology: SARS–CoV–2 has resulted in a global pandemic, sparking urgent vaccine development efforts. The trimeric SARS–CoV–2 spike stabilized in its prefusion conformation by the addition of 2 proline mutations (‘‘SARS–CoV–2 S2P’’) is the antigenic basis of SARS– CoV–2 vaccines that are currently authorized for use in the United States. Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) sought to optimize the presentation of SARS–CoV–2 S2P to the immune system with the goal of eliciting a strong and durable immune response. The researchers designed fusion proteins made of SARS–CoV–2 S2P and Newcastle Disease fusion transmembrane domain and cytosolic tail which form virus like particles (VLPs) displaying the SARS–CoV–2 S2P on the particle surface. SARS–CoV–2 S2P displaying Newcastle Disease virus-like particles (‘‘S2P–NDVLP’’) elicited a robust immune response two weeks after a single immunization. The S2P–NDVLP also elicited an improved immunogenicity despite delivering a PO 00000 Frm 00080 Fmt 4703 Sfmt 4703 Average burden per response Total burden hours lower number of SARS–CoV–2 S2P antigens than the soluble SARS–CoV–2 S2P to which they were compared. This improved immunogenicity is likely due to several characteristics of S2P– NDVLPs such as the mass and large size of the VLP particle that can result in a strong immune response and increase uptake of the S2P by dendritic cells Displaying multiple SARS–CoV–2 S2P on a single particle could allow multiple B-cell receptors on individual B cells to bind that single particle, thereby crosslinking the B-cell receptors and activating those B cells. Lastly, the lipid membrane of the S2P–NDVLP could allow the immunogen to more closely mimic the real virus and boost immune response. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404. Potential Commercial Applications: • A single dose SARS–CoV–2 vaccine Competitive Advantages: • S2P–NDVLP with potential to elicit higher levels of neutralizing antibodies than current vaccines with a single dose Development Stage: Preclinical Research. Inventors: Peter D. Kwong (NIAID); Yongping Yang (NIAID); Wei Shi (NIAID); John R. Mascola (NIAID); Olubukola Abiona (NIAID); Kizzmekia Corbett (NIAID); Barney Graham (NIAID). Publications: Yang, Y et al., (2021). Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS– E:\FR\FM\06APN1.SGM 06APN1 Federal Register / Vol. 86, No. 64 / Tuesday, April 6, 2021 / Notices COV–2 Spikes Elicit Potent Neutralizing Responses. Vaccines, 9(2), 73. Intellectual Property: HHS Reference Number E–068–2021 includes U.S. Provisional Patent Application Number 63/140,250, filed 01/21/2021. Licensing Contact: To license this technology, please contact Amy F. Petrik, Ph.D., 240–627–3721; amy.petrik@nih.gov. Dated: March 24, 2021. Surekha Vathyam, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2021–06997 Filed 4–5–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Aging; Notice of Closed Meetings khammond on DSKJM1Z7X2PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Aging Special Emphasis Panel; Alzheimer’s Disease Drug Development. Date: June 4, 2021. Time: 12:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Video Meeting). Contact Person: Alexander Parsadanian, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National Institutes of Health, Gateway Building, 2C/212, 7201 Wisconsin Avenue, Bethesda, MD 20892, 301–496–9666, parsadaniana@nia.nih.gov. Name of Committee: National Institute on Aging Special Emphasis Panel; Mitochondria and Aging. Date: June 14, 2021. Time: 11:30 a.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Video Meeting). VerDate Sep<11>2014 17:34 Apr 05, 2021 Jkt 253001 Contact Person: Bita Nakhai, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National Institutes of Health, Gateway Bldg., 2C212, 7201 Wisconsin Avenue, Bethesda, MD 20892, 301–402–7701, nakhaib@nia.nih.gov. Name of Committee: National Institute on Aging Special Emphasis Panel; Vascular Dysfunction in AD and Genetic Rick Factors. Date: June 15, 2021. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Video Meeting). Contact Person: Alexander Parsadanian, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National Institutes of Health, Gateway Building, 2C/212, 7201 Wisconsin Avenue, Bethesda, MD 20892, 301–496–9666, parsadaniana@nia.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) Dated: April 1, 2021. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–07053 Filed 4–5–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; PAR19–319: NIDDK Central Repositories Non-renewable Sample Access (X01). Date: May 28, 2021. Time: 2:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy PO 00000 Frm 00081 Fmt 4703 Sfmt 4703 17847 Boulevard, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Najma S. Begum, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, 6707 Democracy Boulevard, Room 7349, Bethesda, MD 20892–5452, (301) 594–8894, begumn@niddk.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) Dated: April 1, 2021. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–07052 Filed 4–5–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Neurobiology of Pain and Itch. Date: April 14, 2021. Time: 2:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: M. Catherine Bennett, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5182, MSC 7846, Bethesda, MD 20892, 301–435– 1766, bennettc3@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, E:\FR\FM\06APN1.SGM 06APN1

Agencies

[Federal Register Volume 86, Number 64 (Tuesday, April 6, 2021)]
[Notices]
[Pages 17846-17847]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-06997]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Amy F. Petrik, Ph.D., 240-627-3721; 
[email protected]. Licensing information and copies of the U.S. patent 
application listed below may be obtained by communicating with the 
indicated licensing contact at the Technology Transfer and Intellectual 
Property Office, National Institute of Allergy and Infectious Diseases, 
5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows:

Newcastle Disease Virus-Like Particle Displaying Prefusion Stabilized 
SARS-CoV-2 Spike and Its Use

    Description of Technology:
    SARS-CoV-2 has resulted in a global pandemic, sparking urgent 
vaccine development efforts. The trimeric SARS-CoV-2 spike stabilized 
in its prefusion conformation by the addition of 2 proline mutations 
(``SARS-CoV-2 S2P'') is the antigenic basis of SARS-CoV-2 vaccines that 
are currently authorized for use in the United States.
    Researchers at the Vaccine Research Center (VRC) of the National 
Institute of Allergy and Infectious Diseases (NIAID) sought to optimize 
the presentation of SARS-CoV-2 S2P to the immune system with the goal 
of eliciting a strong and durable immune response. The researchers 
designed fusion proteins made of SARS-CoV-2 S2P and Newcastle Disease 
fusion transmembrane domain and cytosolic tail which form virus like 
particles (VLPs) displaying the SARS-CoV-2 S2P on the particle surface.
    SARS-CoV-2 S2P displaying Newcastle Disease virus-like particles 
(``S2P-NDVLP'') elicited a robust immune response two weeks after a 
single immunization. The S2P-NDVLP also elicited an improved 
immunogenicity despite delivering a lower number of SARS-CoV-2 S2P 
antigens than the soluble SARS-CoV-2 S2P to which they were compared. 
This improved immunogenicity is likely due to several characteristics 
of S2P-NDVLPs such as the mass and large size of the VLP particle that 
can result in a strong immune response and increase uptake of the S2P 
by dendritic cells Displaying multiple SARS-CoV-2 S2P on a single 
particle could allow multiple B-cell receptors on individual B cells to 
bind that single particle, thereby cross-linking the B-cell receptors 
and activating those B cells. Lastly, the lipid membrane of the S2P-
NDVLP could allow the immunogen to more closely mimic the real virus 
and boost immune response.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
    Potential Commercial Applications:

 A single dose SARS-CoV-2 vaccine

    Competitive Advantages:

     S2P-NDVLP with potential to elicit higher levels of 
neutralizing antibodies than current vaccines with a single dose

    Development Stage: Preclinical Research.
    Inventors: Peter D. Kwong (NIAID); Yongping Yang (NIAID); Wei Shi 
(NIAID); John R. Mascola (NIAID); Olubukola Abiona (NIAID); Kizzmekia 
Corbett (NIAID); Barney Graham (NIAID).
    Publications: Yang, Y et al., (2021). Newcastle Disease Virus-Like 
Particles Displaying Prefusion-Stabilized SARS-

[[Page 17847]]

COV-2 Spikes Elicit Potent Neutralizing Responses. Vaccines, 9(2), 73.
    Intellectual Property: HHS Reference Number E-068-2021 includes 
U.S. Provisional Patent Application Number 63/140,250, filed 01/21/
2021.
    Licensing Contact: To license this technology, please contact Amy 
F. Petrik, Ph.D., 240-627-3721; [email protected].

    Dated: March 24, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-06997 Filed 4-5-21; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.